-
Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry
•
Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum of understanding (MoU) with China Meheco International, a move that will facilitate the export of Daewoong’s pharmaceutical products into the Chinese market. This comprehensive agreement encompasses the entire portfolio of Daewoong’s products, including their innovative…
-
Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu
•
South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has been filed in China for Fexuclu/Abcito (fexuprazan) in a 40mg dosage form. Fexuclu, an in-house developed potassium-competitive acid blocker (P-CAB), represents a new generation of therapies for gastroesophageal reflux disease (GERD). Advantages of P-CABs Over…
